Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Open accessThe DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
Abstract
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other’s work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [23]
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,700
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Cited by
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Yau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00604-5 · Cited by 1,106
Self-citationYau, T. (., Park, J. W. (.-W., Finn, R. S. (. S. )., Cheng, A. L. (.-L., Mathurin, P., Edeline, J., Kudo, M. (., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · Cited by 934
Self-citationAdjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Self-citation2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Kudo, M., Ren, Z., Guo, Y., Han, G., Lin, H., Zheng, J., Ogasawara, S., Kim, J. H., Zhao, H., Li, C., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02575-3 · Cited by 342
Self-citationChanging epidemiology of hepatocellular carcinoma in Asia
Zhang, C., Cheng, Y., Zhang, S., Fan, J., & Gao, Q. (2022) · Liver International · doi:10.1111/liv.15251 · Cited by 335
Lyu, N., Wang, X., Li, J.-B., Lai, J.-F., Chen, Q.-F., Li, S.-L., Deng, H.-J., He, M., Mu, L.-W., & Zhao, M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01963 · Cited by 291
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
Wen, N., Cai, Y., Li, F., Ye, H., Tang, W., Song, P., & Cheng, N. (2022) · BioScience Trends · doi:10.5582/bst.2022.01061 · Cited by 211
Vitale, A., Cabibbo, G., Iavarone, M., Viganò, L., Pinato, D. J., Ponziani, F. R., Lai, Q., Casadei-Gardini, A., Celsa, C., Galati, G., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00186-9 · Cited by 206
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Huang, D. Q., Singal, A. G., Kanwal, F., Lampertico, P., Buti, M., Sirlin, C. B., Nguyen, M. H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00818-8 · Cited by 189
“year in each prefecture, free testing for HBV and HCV is available, and the costs of HCC surveillance are covered by the national health insurance system 156,158 .”
BackgroundXie, D.-Y., Zhu, K., Ren, Z.-G., Zhou, J., Fan, J., & Gao, Q. (2023) · Hepatobiliary Surgery and Nutrition · doi:10.21037/hbsn-22-469 · Cited by 162
“The Barcelona Clinic Liver Cancer (BCLC) group and the Japanese Society of Hepatology (JSH) have also updated recommendations on the staging and treatment allocations of HCC recently (5,6).”
Breakthroughs in Hepatocellular Carcinoma Therapies
Singal, A. G., Kudo, M., & Bruix, J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.039 · Cited by 162
Self-citationKudo, M., Aoki, T., Ueshima, K., Tsuchiya, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Minami, Y., Ida, H., et al. (2023) · Liver Cancer · doi:10.1159/000529574 · Cited by 158
Self-citationKudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., Izumi, N., Yamasaki, T., Nojiri, S., Hino, K., et al. (2022) · Liver Cancer · doi:10.1159/000522547 · Cited by 141
Self-citation2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
(2022) · Korean Journal of Radiology · doi:10.3348/kjr.2022.0822 · Cited by 149
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
(2022) · Journal of Liver Cancer · doi:10.17998/jlc.2022.11.07 · Cited by 153
Evolving Global Etiology of Hepatocellular Carcinoma (HCC): Insights and Trends for 2024
Koshy, A. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.102406 · Cited by 153
Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing Tides
Khan, A. R., Wei, X., & Xu, X. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s318070 · Cited by 123
Kudo, M., Ueshima, K., Saeki, I., Ishikawa, T., Inaba, Y., Morimoto, N., Aikata, H., Tanabe, N., Wada, Y., Kondo, Y., et al. (2023) · Liver Cancer · doi:10.1159/000531377 · Cited by 115
“The results of this proof-of-concept trial were presented as evidence for establishing the concept of TACE ineligibility and for recommending upfront LEN followed by locoregional therapy in the APPLE Consensus [22] and JSH Consensus [23].”
MethodResultSelf-citationImaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives
Ronot, M., Chernyak, V., Burgoyne, A. M., Chang, J., Jiang, H., Bashir, M. R., & Fowler, K. J. (2023) · Radiology · doi:10.1148/radiol.221429 · Cited by 120
Kudo, M. (2022) · Liver Cancer · doi:10.1159/000526163 · Cited by 100
Self-citationKudo, M. (2021) · Liver Cancer · doi:10.1159/000519749 · Cited by 99
Self-citationIwamoto, H., Shimose, S., Shirono, T., Niizeki, T., & Kawaguchi, T. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0391 · Cited by 97
Trevisani, F., Vitale, A., Kudo, M., Kulik, L., Park, J., Pinato, D. J., & Cillo, U. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.010 · Cited by 105
Self-citationKudo, M., Finn, R. S., Galle, P. R., Zhu, A. X., Ducreux, M. P., Cheng, A., Ikeda, M., Tsuchiya, K., Aoki, K.-I., Jia, J., et al. (2022) · Liver Cancer · doi:10.1159/000528272 · Cited by 95
“…this was the longest median OS reported in a phase III study of 1 L systemic therapy for unresectable HCC. Recent EASL, AASLD, and Japan Society of Hepatology guidelines recommend atezolizumab + bevacizumab as the preferred treatment option in systemic treatment-naive patients with HCC [8, 13, 14].”
BackgroundInfluentialSelf-citationCho, Y., Kim, B. H., & Park, J. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0099 · Cited by 103
Pοlyzos, S. A., Chrysavgis, L., Vachliotis, I. D., Chartampilas, E., & Cholongitas, Ε. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.010 · Cited by 97
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
Lau, G. K. K., Obi, S., Zhou, J., Tateishi, R., Qin, S., Zhao, H., Otsuka, M., Ogasawara, S., George, J., Chow, P. K. H., et al. (2024) · Hepatology International · doi:10.1007/s12072-024-10732-z · Cited by 106
“However, due to the scarcity of organ and living donors in the Asia–Pacific region, many such patients cannot obtain timely liver transplantation as a curative measure [10, 52–54].”
Self-citationRole of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
Zhong, B., Jin, Z., Chen, J.-J., Zhu, H., & Zhu, X. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00293 · Cited by 99
Guan, M., Zhang, S., Ding, Q., Li, N., Fu, T., Zhang, G., He, Q., Shen, F., Yang, T., & Zhu, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030949 · Cited by 86
“Generally, the three tumor markers have been utilized in various clinical settings in East Asian and Western countries [13,14].”
BackgroundYau, T. C. C., Zagonel, V., Santoro, A., Acosta-Rivera, M., Choo, S. P., Matilla, A., He, A. R., Gracián, A. C., El-Khoueiry, A. B., Sangro, B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00972 · Cited by 76
“PD 6 (17) 7 (19) 4 (11) 4 (11) Non-CR/non-PD — 3 (8) — 1 (3) Unable to determine 1 (3) 1 (3) 2 (6) 3 (9) DCR, No.”
InfluentialFu, Y., Peng, W. J., Zhang, W., Yang, Z., Hu, Z., Pang, Y., Hu, D., Chen, J., Wang, J., Zhou, Z., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-01976-x · Cited by 65
“& Minshan Chen chenmsh@sysucc.org.cn & Yaojun Zhang zhangyuj@sysucc.org.cn 1 Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People’s Republic of China 2 Department of Liver Surgery, Sun Yat-Sen Uni…”
BackgroundInfluentialEpidemiology of liver diseases: global disease burden and forecasted research trends
Xiao, J., Wang, F., Yuan, Y., Gao, J., Lu, X., Chao, Y., Guo, F., Zhong, J., Che, Z., Li, W., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2722-2 · Cited by 74
“As early as 2013, Japan ranked second after China in terms of deaths from primary liver cancer, and in recent years, the average annual incidence and mortality rates in Japan have been increasing (Kudo et al., 2021).”
Kudo, M. (2021) · Liver Cancer · doi:10.1159/000521374 · Cited by 62
Self-citationArterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
Zhao, M. D., Guo, Z., Zou, Y., Li, X., Yan, Z.-P., Chen, M., Fan, W., Li, H.-L., Yang, J., Chen, X., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10599-6 · Cited by 74
“The Japan Society of Hepatology practice guidelines for HCC have recognized HAIC as an effective treatment for locally advanced HCC since 1995 [16, 21].”
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Liu, L., Wen, T., Kuang, M., Zhang, B., et al. (2025) · Liver Cancer · doi:10.1159/000546574 · Cited by 153
Piratvisuth, T., Hou, J., Tanwandee, T., Berg, T., Vogel, A., Trojan, J., Toni, E. N. D., Kudo, M., Eiblmaier, A., Klein, H., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000317 · Cited by 74
“[22] The HCC group included patients with a first-time diagnosis of HCC that had been confirmed radiologically (in accordance with international guidelines [5,7,23] ) or by liver biopsy within 6 months of enrollment.”
MethodSelf-citationMaesaka, K., Sakamori, R., Yamada, R., Doi, A., Tahata, Y., Miyazaki, M., Ohkawa, K., Mita, E., Iio, S., Nozaki, Y., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13771 · Cited by 60
Self-citationXin, Y., Cao, F., Yang, H., Zhang, X., Chen, Y., Cao, X., Zhou, X., Li, X., & Zhou, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929141 · Cited by 56
“Hepatic arterial infusion chemotherapy (HAIC), as locoregional interventional therapy, can enhance tumor response rate and reduce systemic toxicity by increasing local chemotherapeutic drug concentrations within tumor tissue (20– 22) and has been recommended as one of the first-line options for patients with advanced…”
BackgroundStella, L., Santopaolo, F., Gasbarrini, A., Pompili, M., & Ponziani, F. R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i21.2251 · Cited by 70
Locoregional Therapies for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Patel, K. R., Menon, H., Patel, R. R., Huang, E. P., Verma, V., & Escorcia, F. E. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.47995 · Cited by 69
Hiraoka, A., Kumada, T., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2021) · Hepatology Research · doi:10.1111/hepr.13734 · Cited by 55
Self-citationStereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
Matsuo, Y. (2023) · Current Oncology · doi:10.3390/curroncol30020190 · Cited by 59
“The situation is the same in the Japanese Guidelines, which do not allude to any role of radiotherapy in the management of HCC [6].”
BackgroundSu, T., Wu, C., Liu, T., Ho, C., & Liu, C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0421 · Cited by 54
Hatanaka, T., Yata, Y., Naganuma, A., & Kakizaki, S. (2023) · Cancers · doi:10.3390/cancers15061798 · Cited by 55
“Molecular-targeted drugs with an anti-VEGF effect act on tumor blood vessels to improve the vascular permeability; reduce the tumor interstitial pressure; improve the drug delivery; enhance the treatment efficacy [34]; and suppress the effect of the transient increase of VEGF immediately after the occurrence of TACE-r…”
BackgroundZou, X., Xu, Q., You, R., & Yin, G. (2023) · Cancer Medicine · doi:10.1002/cam4.5841 · Cited by 54
Ikeda, M., Yamashita, T., Ogasawara, S., Kudo, M., Inaba, Y., Morimoto, M., Tsuchiya, K., Shimizu, S., Kojima, Y., Hiraoka, A., et al. (2023) · Liver Cancer · doi:10.1159/000531820 · Cited by 46
“Therefore, in some countries, especially China, HAIC with FOLFOX is often used in advanced HCC patients [1, 9].”
BackgroundMethodInfluentialSelf-citationKuroda, H., Oikawa, T., Ninomiya, M., Fujita, M., Abe, K., Okumoto, K., Katsumi, T., Sato, W., Igarashi, G., Iino, C., et al. (2022) · Liver Cancer · doi:10.1159/000522424 · Cited by 47
Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice
Desjonqueres, E., Campani, C., Marra, F., Zucman‐Rossi, J., & Nault, J. (2022) · Liver International · doi:10.1111/liv.15152 · Cited by 50
Xia, D., Bai, W., Wang, E., Li, J., Chen, X., Wang, Z., Huang, M., Huang, M. X., Sun, J., Weizhu, Y., et al. (2022) · Liver Cancer · doi:10.1159/000523849 · Cited by 48
Sim, Y. K., Chong, M. C., Gandhi, M., Pokharkar, Y. M., Zhu, Y., Shi, L., Li, L., Chen, C., Kudo, M., Lee, J. H., et al. (2023) · Liver Cancer · doi:10.1159/000534513 · Cited by 57
“Regional professional guidelines, including those from China [25], Taiwan [26], Hong Kong [27], Korea [28], Japan [29], Australia [30], and Singapore [15, 31], have been established in attempts to guide therapeutic decisions, but their concordance and impact on real world practices are uncertain.”
BackgroundSelf-citationLi, X., Fu, Z., Chen, X., Cao, K., Zhong, J., Liu, L., Ding, N., Zhang, X., Zhai, J., & Qu, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.950266 · Cited by 41
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
Kudo, M. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02166-0 · Cited by 40
Self-citationGuan, R., Zhang, N., Deng, M., Lin, Y., Huang, G., Fu, Y., Zheng, Z., Wei, W., Zhong, C., Zhao, H., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001378 · Cited by 42
“In addition to LEN-P, more aggressive treatments, such as hepatic arterial infusion chemotherapy (HAIC), have been adopted in the Asia-Paci fi c region [10,11] .”
BackgroundTreatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions
Jonas, E., Bernon, M. M., Robertson, B., Kassianides, C., Keli, E., Offei, A. K., Alatise, O. I., Okello, M., Oumarou, B. N., Mulehane, K. O., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00042-5 · Cited by 42
Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
Cheon, J., Kim, H., Kim, H. S., Kim, C. G., Kim, I. H., Kang, B., Kim, C., Jung, S., Ha, Y., & Chon, H. J. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148541 · Cited by 36
Yang, Z., Wang, X., Fu, Y., Wu, W., Hu, Z., Lin, Q., Peng, W. J., Pan, Y., Wang, J., Chen, J., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02097-6 · Cited by 40
“Oxaliplatin (OXA)-based chemotherapy has been used as a standard therapeutic modality in the management of liver cancer and colorectal cancer (CRC) [8–10].”
Johnson, P. J., Kalyuzhnyy, A., Boswell, E., & Toyoda, H. (2024) · BJC Reports · doi:10.1038/s44276-024-00050-0 · Cited by 45
“…most appropriate for surveillance, the population is intensively involved within the programme and many people perceive that they may be at heightened risk of HCC because of chronic viral hepatitis [6]; such patients are not excluded from the surveillance programme even in the absence of cirrhosis.”
BackgroundSelf-citationLocoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Zane, K. E., & Makary, M. S. (2021) · Cancers · doi:10.3390/cancers13215430 · Cited by 38
“While included in Japanese treatment guidelines for advanced HCC [60], it is less commonly performed for advanced HCC in the United States.”
BackgroundLi, L., Wu, P., Liang, X., Chen, K., Zhang, G.-L., Su, Q.-B., Huo, R., Xie, R.-W., Huang, S. H., Ma, L., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02018-2 · Cited by 38
“Hepatic resection is one of the main curative treatments for patients with early-stage hepatocellular carcinoma (HCC) [1, 2], and at least in several Asian countries, it is also recommended for intermediate and advanced disease involving adequate liver function [3, 4].”
BackgroundMolecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure
Li, J., Liu, Y., Zheng, R., Qu, C., & Li, J. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122540 · Cited by 37
Medicinal plants and their utilization by villagers in southern districts of Tamil Nadu.
Rajendran, K., Balaji, P., & Basu, M. J. (2008) · Indian Journal of Traditional Knowledge · Cited by 34
Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma
Minami, Y., Aoki, T., Hagiwara, S., & Kudo, M. (2023) · Cancers · doi:10.3390/cancers15194763 · Cited by 35
Self-citationShin, H., & Yu, S. J. (2025) · Journal of Liver Cancer · doi:10.17998/jlc.2025.02.03 · Cited by 44
Watanabe, Y., Aikawa, M., Kato, T., Takase, K., Watanabe, Y., Okada, K., Okamoto, K., & Koyama, I. (2022) · Surgical Endoscopy · doi:10.1007/s00464-022-09677-x · Cited by 33
“However, the strategy for recurrent HCC at our institution is the optimal treatment according to the guidelines of the Japan Society of Hepatology of the era of the study period, and we believe that the emergence of novel therapies had only a limited influence on the present study.”
MethodSurveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update
Kudo, M. (2023) · Liver Cancer · doi:10.1159/000530079 · Cited by 32
Self-citationBeudeker, B. J. B., Fu, S., Balderramo, D. C., de Mattos, Â. Z., Carrera, E., Ferrer, J. D., Prieto, J. E., Bañales, J. M., Vogel, A., Arrese, M. A., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000264 · Cited by 32
Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy
Zhou, X.-H., Li, J., Zheng, T., Chen, H., Cai, C., Ye, S., Gao, B., & Xue, T. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-022-10188-1 · Cited by 35
Cai, M., Huang, W., Liang, W. Y., Guo, Y., Liang, L., Lin, L., Xie, L., Zhou, J., Chen, Y., Cao, B., et al. (2024) · Liver International · doi:10.1111/liv.15831 · Cited by 34
“2,4,30 Similarly, in another randomized trial enrolling patients with more advanced HCC (34.4% of the patients receiving Len-TACE had portal trunk invasion, with a mean target tumour diameter of 10.8 cm), the median PFS and OS of Len-TACE were much shorter, being only 4.7 and 14.5 months,…”
BackgroundInfluentialTeng, W., Wang, H., Lin, S., & On behalf of Diagnosis Group and Systemic Therapy Group of TLCA (2024) · Liver Cancer · doi:10.1159/000537686 · Cited by 44
“Based on several treatment guidelines, systemic therapy is recommended for patients who are not eligible for effective TACE [10, 86 – 88].”
InfluentialNakagawa, M., Inoue, M., Ogasawara, S., Maruta, S., Okubo, T., Itokawa, N., Iino, Y., Obu, M., Haga, Y., Seki, A., et al. (2022) · Cancer · doi:10.1002/cncr.34559 · Cited by 29
“In the past, many patients received lenvatinib as second‐ or later‐line treatment shortly after it was approved as the first‐line agent for advanced HCC.27 Thus far, immediately after approval, F I GUR E 3 Onset of adverse events caused by atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinom…”
BackgroundInfluentialSelf-citationTherapeutic Effects of Natural Products on Liver Cancer and Their Potential Mechanisms
Guo, J., Yan, W., Duan, H., Wang, D., Zhou, Y., Feng, D., Zheng, Y., Zhou, S., Liu, G., & Qin, X. (2024) · Nutrients · doi:10.3390/nu16111642 · Cited by 36
“It effectively reduces large liver cancers beyond Milan criteria and can act as a bridge to transplantation [19].”
BackgroundSugimoto, K., Imajo, K., Kuroda, H., Murohisa, G., Shiozawa, K., Sakamaki, K., Wada, T., Takeuchi, H., Endo, K., Abe, T., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101269 · Cited by 29
Self-citationKudo, M. (2021) · Cancers · doi:10.3390/cancers13215475 · Cited by 32
“Thus, the concept of TACE unsuitability has been recently raised at the Asia–Pacific Primary Liver Cancer Expert (APPLE) Consensus [46] and the Clinical Practice Manual for Hepatocellular Carcinoma (JSH consensus) [36].”
BackgroundSelf-citationImmunotherapy in older patients with hepatocellular carcinoma
Lyu, N., Yi, J., & Zhao, M. D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.024 · Cited by 31
Renzulli, M., Pecorelli, A., Brandi, N., Brocchi, S., Tovoli, F., Granito, A., Carrafiello, G., Ierardi, A. M., & Golfieri, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154399 · Cited by 28
“The advent of new direct-acting antivirals (DAAs) against HCV, together with the widespread use of MRI performed with hepato-specific contrast agents, has opened a new chapter in the investigation and management of nodules without arterial hypervascularisation [21,22].”
BackgroundGuan, M., Ouyang, W., Liu, S., Sun, L., Chen, W.-Y., Tong, X., Zhu, H., & Yang, T. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.05.003 · Cited by 30
Clinical Significance of Liver MR Imaging
Ichikawa, S., & Goshima, S. (2023) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.rev.2022-0100 · Cited by 32
Maesaka, K., Sakamori, R., Yamada, R., Doi, A., Tahata, Y., Ohkawa, K., Oshita, M., Miyazaki, M., Yakushijin, T., Nozaki, Y., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281459 · Cited by 30
Self-citationThe management and outcomes of hepatocellular carcinoma in sub-Saharan Africa: a systematic review
Sobnach, S., Kotze, U. K., Spearman, C. W., Sonderup, M. W., Nashidengo, P. R., Ede, C. J., Keli, E., Chihaka, O. B., Zerbini, L. F., Li, Y. J., et al. (2023) · HPB · doi:10.1016/j.hpb.2023.09.015 · Cited by 27
Kudo, M. (2024) · Liver Cancer · doi:10.1159/000537897 · Cited by 27
“This increase in detection is likely due to the fact that Japanese practice guidelines [6, 7] do not de fi ne non-cirrhotic MASLD/ MASH patients as high risk or super high risk for developing HCC; thus, even the established and successful Japanese surveillance program may not be suf fi cient to…”
BackgroundSelf-citationMagyar, C. T. J., O'Kane, G. M., Aceituno, L., Li, Z., Vogel, A., Bruix, J., Mazzaferro, V., & Sapisochín, G. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00857 · Cited by 31
Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update
Kudo, M. (2021) · Liver Cancer · doi:10.1159/000516491 · Cited by 29
Self-citationMatsumoto, H., Tsuchiya, K., Nakanishi, H., Hayakawa, Y., Yasui, Y., Uchihara, N., Suzuki, K., Tanaka, Y., Miyamoto, H., Ishido, S., et al. (2022) · Cancers · doi:10.3390/cancers14143551 · Cited by 27
“The Japanese Ministry of Health, Labour, and Welfare had no role in the design of the study; the collection, analysis, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.”
MethodInfluentialSelf-citationWada, T., Sugimoto, K., Sakamaki, K., Takahashi, H., Kakegawa, T., Tomita, Y., Abe, M., Yoshimasu, Y., Takeuchi, H., & Itoi, T. (2023) · Cancers · doi:10.3390/cancers15030732 · Cited by 27
“Accordingly, RFA is indicated for patients with up to three HCCs that are < 3 cm in diameter and Child-Pugh class A or B liver function [2,3].”
BackgroundMethodLi, S.-Q., Wu, J., Wu, J., Xie, H., Li, J.-H., Zeng, Z.-X., Fu, Y.-K., Liu, D.-Y., Han, L., Chen, W.-Z., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s428980 · Cited by 27
“However, experts from Eastern countries have recognized that in selected patients with HCC and PVTT, surgical treatment can improve quality of life and prolong survival.(2,30,31) Most studies do not recommend surgery for Vp4 patients as they do not obtain survival benefits from resection.”
BackgroundCai, M., Liang, L., Zhang, J., Chen, N., Huang, W., Guo, Y., Hong, X., Lin, L., Liu, Y., Dan, C., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001819 · Cited by 31
“Notably, the extent of PVTT is closely associated with patient survival [3,5] .”
InfluentialKudo, M., Ikeda, M., Ueshima, K., Sakamoto, M., Shiina, S., Tateishi, R., Nouso, K., Hasegawa, K., Furuse, J., Miyayama, S., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13746 · Cited by 27
Self-citationToshida, K., Itoh, S., Tomiyama, T., Morinaga, A., Kosai‐Fujimoto, Y., Tomino, T., Kurihara, T., Nagao, Y., Morita, K., Harada, N., et al. (2022) · JGH Open · doi:10.1002/jgh3.12777 · Cited by 27
Hosoda, S., Suda, G., Sho, T., Ogawa, K., Kimura, M., Yang, Z., Yoshida, S., Kubo, A., Tokuchi, Y., Kitagataya, T., et al. (2022) · Liver Cancer · doi:10.1159/000527759 · Cited by 27
Protein induced by vitamin K absence or antagonist II: Experience to date and future directions
Dong, L., Qiu, X., Gao, F., Wang, K., & Xu, X. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189016 · Cited by 34
Man, K.-F., Zhou, L., Yu, H., Lam, K.-H., Cheng, W., Yu, J., Lee, T. K., Yun, J., Guan, X., Liu, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43670-9 · Cited by 33
“The use of 5-FU and cisplatin chemotherapies, often administered through transarterial chemoembolization 17 and hepatic artery infusion chemotherapy 18,19 , are commonly adopted in clinical practice for management of intermediate/advanced HCC patients.”
BackgroundMatsufuji, S., Kitajima, Y., Higure, K., Kimura, N., Maeda, S., Yamada, K., Ito, K., Tanaka, T., Kai, K., & Noshirο, H. (2023) · Cancer & Metabolism · doi:10.1186/s40170-023-00328-w · Cited by 30
“Hepatic resection or ablation is recommended as the primary treatment method for HCC when liver function is preserved [4].”
BackgroundMethodKuo, Y., Lu, S., Chen, Y., Kee, K., Yen, Y., Hung, C., Hu, T., Chen, C., & Wang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.737767 · Cited by 27
Omar, A., Kaseb, A. O., Elbaz, T. M., El‐Kassas, M., Fouly, A. E., Hanno, A., Dorry, A. E., Hosni, A. N., Helmy, A., Saad, A. S., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s404424 · Cited by 27
“45 In a study conducted in Egypt on 83 patients, PIVKA-II was highly sensitive, specific, and superior to AFP monitoring in the early detection of HCC patients.”
BackgroundInfluentialKobayashi, K., Ogasawara, S., Maruta, S., Okubo, T., Itokawa, N., Haga, Y., Seko, Y., Moriguchi, M., Watanabe, S., Shiko, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1462 · Cited by 27
Self-citationKudo, M. (2024) · Liver Cancer · doi:10.1159/000539301 · Cited by 24
Self-citationYang, C., Luo, Y., Yang, H., Yao, Z.-H., & Li, X. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s373112 · Cited by 24
Metadata
- Authors
- Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., Izumi, N., Moriguchi, M., Ogasawara, S., Minami, Y., Ueshima, K., Murakami, T., Miyayama, S., Nakashima, O., Yano, H., Sakamoto, M., Hatano, E., Shimada, M., Kokudo, N., Mochida, S., Takehara, T., & HCC Expert Panel of the Japan Society of Hepatology
- Affiliations
- Kindai University Hospital (JP)
- Toranomon Hospital (JP)
- The University of Tokyo (JP)
- Okayama City Hospital (JP)
- Juntendo University (JP)
- Ogaki Municipal Hospital (JP)
- Ikeda Municipal Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- National Cancer Center Hospital East (JP)
- Musashino Red Cross Hospital (JP)
- Kyoto Prefectural University of Medicine (JP)
- Chiba University (JP)
- Kobe University (JP)
- Fukui-ken Saiseikai Hospital (JP)
- Kurume University (JP)
- Keio University (JP)
- Hyogo Medical University (JP)
- Tokushima University (JP)
- National Center for Global Health and Medicine (JP)
- Saitama Medical University (JP)
- The University of Osaka (JP)
- ORCID
- Kudo, Masatoshi
- Kawamura, Yusuke
- Hasegawa, Kiyoshi
- Tateishi, Ryosuke
- Kariyama, Kazuya
- Shiina, Shuichiro
- Toyoda, Hidenori
- Hiraoka, Atsushi
- Ikeda, Masafumi
- Izumi, Namiki
- Moriguchi, Michihisa
- Ogasawara, Sadahisa
- Minami, Yasunori
- Ueshima, Kazuomi
- Murakami, Takamichi
- Miyayama, Shiro
- Nakashima, Osamu
- Yano, Hirohisa
- Sakamoto, Michiie
- Hatano, Etsuro
- Shimada, Mitsuo
- Kokudo, Norihiro
- Mochida, Satoshi
- Takehara, Tetsuo
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2021
- Volume
- 10
- Issue
- 3
- Pages
- 181-223
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- PMC
- PMC8237791
- OpenAlex
- W3162270595
- Cited by
- 678
- References
- 200
- Citations by year
- 2026: 78 · 2025: 137 · 2024: 158 · 2023: 177 · 2022: 108 · 2021: 17
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Liver Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc)
- Funders
- Japan Society for the Promotion of Science (19K08199)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, consensus statement, clinical guidelines, HCC diagnosis, HCC treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.